Reply to: Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: Should we switch biologic?

We thank Dr. Evangelatos for his interest in the guideline and his efforts to provide further clarity to this clinical scenario. During the guideline process, the voting panel thoroughly discussed many of these aspects of hypogammaglobulinemia during rituximab treatment that Dr. Evangelatos has adeptly described.